Granted Patent
B2
US 8,183,280 · App. 11/991,286 · Granted May 22, 2012
FAP inhibitors
Assignee:
Vantia Limited
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention concerns compounds, according to general formula (I), which find utility preferably for the treatment of cancer.
Claims (4)
1. (2S)-1-(2-(1-Napthoylamino)acetyl)pyrrolidine-2-carbonitrile, or a pharmaceutically acceptable salt form thereof.
2. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable excipient.
3. The pharmaceutical composition according to claim 2 , formulated for oral administration.
4. The pharmaceutical composition of claim 3 , formulated as a tablet, capsule, or satchet.
Assignments (2)
CORRECTIVE ASSIGNMENT TO CORRECT THE CORRECTIVE ASSIGNMENT TO CORRECT THE ASSINGNEE'S ADDRESS PREVIOUSLY RECORDED AT REEL 022266 FRAME 0100. PREVIOUSLY RECORDED ON REEL 022266 FRAME 0100. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT.
Recorded Mar 10, 2009
From: FERRING BV
To: VANTIA LIMITED
Reel/Frame 022368/0479 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Feb 17, 2009
From: FERRING BV
To: VANTIA LIMITED
Reel/Frame 022266/0100 →
Priority Claims (1)
EP 05108049
· Sep 2, 2005
· regional
Continuity (2)
Provisional Application
60713324
· Sep 2, 2005